Final results from a large-scale Phase III trial of the RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet, show that the vaccine candidate helped protect children and infants from clinical malaria for at least three years after first vaccination.
The latest results demonstrated that vaccination with RTS,S, followed by a booster dose of RTS,S administered 18 months after the primary schedule, reduced the number of cases of clinical malaria in children (aged 5-17 months at first vaccination) by 36% to the end of the study1 (over an average follow-up of 48 months across trial sites) and in infants (aged 6-12 weeks at first vaccination) by 26% to the end of the study (over an average follow-up of 38 months across trial sites). Efficacy decreased over time in both age groups. Without the booster dose, the 3-dose primary schedule reduced clinical malaria cases by 28% in children and 18% in infants to the study end. The efficacy of RTS,S was evaluated in the context of existing malaria control measures, such as insecticide treated bed nets, which were used by approximately 80% of the children and infants in the trial.
For children in the 5-17 month age category who received a booster dose 18 months after the primary schedule, an average of 1,774 cases of clinical malaria were prevented for every 1,000 children vaccinated across the trial sites, over an average of 48 months of follow-up. For infants aged 6-12 weeks at first vaccination with RTS,S, who received a booster dose, 983 cases of clinical malaria, on average, were prevented for every 1,000 infants vaccinated across trial sites over an average of 38 months of follow-up. More cases were averted in areas of higher malaria transmission. In the absence of a booster dose, 1,363 cases of clinical malaria were prevented, on average, for every 1,000 children aged 5-17 months at first vaccination and 558 cases for every 1,000 infants aged 6-12 weeks at first vaccination to the end of the study.
Statistically significant efficacy against severe malaria to the end of the study period was observed only in children who received the booster dose. There was indication of increased risk for severe malaria in children who did not receive the booster dose, compared to those in the control group.
Eleven research centres in seven African countries2 conducted the efficacy and safety trial, in partnership with GSK and the PATH Malaria Vaccine Initiative (MVI), with grant funding from the Bill & Melinda Gates Foundation to MVI. The trial, started in March 2009 and concluded in January 2014, enrolled 15,459 participants, in two age categories: children (aged 5-17 months at first vaccination) and infants (aged 6-12 weeks at first vaccination).
RTS,S continued to display an acceptable safety and tolerability profile during the entire study period.
The incidence of fever in the week after vaccination was higher in children who received RTS,S than in those receiving control vaccine. In some children who experienced fever, the febrile reaction was accompanied by generalized convulsions, but all those affected fully recovered within seven days.
The meningitis signal previously reported remains in the older age category, including two cases reported after the booster dose of RTS,S. This could be a chance finding, as comparisons were made across groups for many different diseases, and because some of these cases happened years after vaccination without any obvious relationship to vaccination. The occurrence of meningitis will be followed closely during Phase IV studies, if RTS,S is licensed.
Dr Kwaku Poku Asante, a principal investigator in the trial and chairperson of the RTS,S Clinical Trials Partnership Committee said: “We finally have in our sights a candidate vaccine that could have a real impact on this terrible disease that affects many children during their first years of life. The large number of children affected by malaria, sometimes several times per year, means that this vaccine candidate, if deployed correctly, has the potential to prevent millions of cases of malaria.
On behalf of the African scientists and research centers that worked on the RTS,S trial, we give thanks to our national health authorities, and to the trial participants, for enabling us to reach this important milestone.”
Dr Moncef Slaoui, Chairman Global Vaccines at GSK, said: “We are extremely encouraged that the results point to continued and significant public health benefit for those children whose lives are so disrupted by this awful disease. We might reasonably now expect that the impact of this vaccine candidate when used with existing interventions will allow more children to survive the early years which we know is the most dangerous time to be infected with malaria. We are working hard to submit the necessary evidence to regulatory authorities and the World Health Organisation so that they can take an informed decision on whether the RTS,S vaccine candidate should be made available as an additional tool for malaria prevention.”
Dr David C. Kaslow, Vice President of Product Development at PATH, said: “Credit for reaching this scientific milestone goes to the thousands of African families and hundreds of scientists, clinicians, and health professionals who have made a commitment for many years to this vaccine trial. The public-private partnership behind RTS,S has successfully collected pivotal human efficacy and safety data that regulators and policymakers can now use to decide on its use. While eradication is the ultimate goal, malaria has yet to be eliminated or even fully controlled in many parts of the world; these data suggest that malaria vaccines can help us take some critical steps along that path.”
The European Medicines Agency (EMA) is currently reviewing the regulatory application for RTS,S through the Art. 58 procedure initiated in July 2014.
A positive opinion from the EMA’s Committee for Medicinal Products for Human Use, together with a potential policy recommendation from the World Health Organisation (anticipated by the end of 2015), would be the basis for licensure applications to National Regulatory Authorities in sub-Saharan African countries. If positive, these regulatory decisions would help pave the way for the introduction of RTS,S through African national immunisation programmes. If RTS,S is approved, GSK has committed to making the vaccine available at a not-for-profit price.
GSK — one of the world’s leading research-based pharmaceutical and healthcare companies — is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors' in the company's Annual Report on Form 20-F for 2014.
PATH is the leader in global health innovation. An international nonprofit organization, PATH saves lives and improves health, especially among women and children. Accelerating innovation across five platforms–vaccines, drugs, diagnostics, devices, and system and service innovations–PATH harnesses its entrepreneurial insight, scientific and public health expertise, and passion for health equity. By mobilizing partners around the world, PATH takes innovation to scale, working alongside countries primarily in Africa and Asia to tackle their greatest health needs. With these key partners, PATH delivers measurable results that disrupt the cycle of poor health. Learn more atÂ www.path.org.
About the PATH Malaria Vaccine Initiative
The PATH Malaria Vaccine Initiative (MVI) is a global program established at PATH through an initial grant from the Bill & Melinda Gates Foundation. MVI's mission is to accelerate the development of malaria vaccines and catalyze timely access in endemic countries. MVI’s vision is a world free from malaria. For more information, please visit www.malariavaccine.org.
GSK enquiries:Â Â Â
UK Media enquiries:Â David MawdsleyÂ +44 (0) 20 8047 5502Â (London)
Â Simon SteelÂ +44 (0) 20 8047 5502Â (London)
Â David DaleyÂ +44 (0) 20 8047 5502Â (London)
Â Catherine HartleyÂ +44 (0) 20 8047 5502Â (London)
Â Sarah SpencerÂ +44 (0) 20 8047 5502Â (London)
Â Claire BroughÂ +44 (0) 20 8047 5502Â (London)
Â Â Â
US Media enquiries:Â Sarah AlspachÂ +1 202 715 1048Â (Washington, DC)
Â Mary Anne RhyneÂ +1 919 483 0492Â (North Carolina)
Â Melinda StubbeeÂ +1 919 483 2510Â (North Carolina)
Â Jenni LigdayÂ +1 202 715 1049Â (Washington, DC)
Â Karen HagensÂ +1 919 483 2863Â (North Carolina)
Â Â Â
Analyst/Investor enquiries:Â Ziba ShamsiÂ +44 (0) 20 8047 5543Â (London)
Â Tom CurryÂ + 1 215 751 5419Â (Philadelphia)
Â Gary DaviesÂ +44 (0) 20 8047 5503Â (London)
Â James DodwellÂ +44 (0) 20 8047 2406Â (London)
Â Jeff McLaughlinÂ +1 215 751 7002Â (Philadelphia)
All PATH Malaria Vaccine Initiative (MVI) media enquiries: Ellen Wilson at +1 301 280 5723 or email@example.com.
1 Intention to Treat (ITT) analysis, for this statistical reference and those that follow
2 Burkina Faso, Gabon, Ghana, Kenya, Malawi, Mozambique, and Tanzania